Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, announced that a scientific poster presented at the Society of Interventional Radiology (SIR) conference, featuring data generated using the MicroThermX Microwave Ablation System (MicroThermX), demonstrated a significant advantage for MicroThermX microwave ablation. The study, ‘Impact of Variation in Portal Venous Blood Flow on the Size of Radiofrequency and Microwave Ablation Lesions,’ was conducted by Gerald D. Dodd, III, MD, Nicolas A. Dodd, and Anthony C. Lanctot, MS, Department of Radiology, University of Colorado, School of Medicine. Dodd, one of the pioneers in Radiofrequency (RF) ablation, presented the data from the in-vitro study, which was designed to assess the impact of variations in blood flow on ablation zones produced using the microwave MicroThermX compared to a commercially available RF system. The presentation received an award at the SIR conference.
"Microwave ablation is able to deliver a predictable and reproducible heating pattern that is not influenced by physiological changes in blood flow in the liver," said Dodd. "This is a significant clinical advantage over RF ablation, which is significantly impacted by physiological changes in blood flow in the liver. Predictable and reproducible ablations are a critical element of treatment planning for ablation. Not knowing the size of the ablation that you are going to get when treating a liver tumor leads to both over-treatment and under-treatment. Over-treatment poses the risk of injury to adjacent vital structures, and under-treatment means you didn't 'kill' the tumor. The predictable and reproducible performance of microwave ablation should translate to improved clinical results for cancer patients."